INTERACTION BETWEEN THE PHOSPHODIESTERASE 5 INHIBITOR, TADALAFIL AND 2 α-BLOCKERS, DOXAZOSIN AND TAMSULOSIN IN HEALTHY NORMOTENSIVE MEN
- 1 November 2004
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 172 (5), 1935-1940
- https://doi.org/10.1097/01.ju.0000142687.75577.e4
Abstract
Tadalafil, a phosphodiesterase type 5 inhibitor, is effective therapy for erectile dysfunction (ED). Men with ED have a high incidence of comorbid conditions including cardiovascular disease, diabetes mellitus and benign prostatic hyperplasia. Although phosphodiesterase type 5 inhibitors are safe when administered with most medications, sildenafil given with doxazosin and vardenafil given with terazosin evoke orthostatic hypotension in some patients. We examined the hemodynamic interactions of tadalafil with the α-blockers doxazosin and tamsulosin. In separate double-blind, placebo controlled, randomized crossover studies (18 patients in each study) we evaluated the hemodynamic effects of doxazosin 8 mg with tadalafil 20 mg, and tamsulosin 0.4 mg with tadalafil 10 and 20 mg. Blood pressure (BP) and heart rate were recorded before dosing and for 24 hours after dosing. Tadalafil 20 mg augmented the hypotensive effect of doxazosin by producing a mean maximal decrease in standing systolic BP (SBP) that was significantly greater than placebo (a mean difference of 9.8 mm Hg). Analysis of BP outliers showed that the number of subjects with a standing SBP of less than 85 mm Hg was greater after doxazosin plus tadalafil (28%) versus doxazosin plus placebo (6%). In subjects on tamsulosin, tadalafil 10 and 20 mg produced mean maximal decreases in standing SBP that were similar to placebo (mean difference of 1.7 and 2.3 mm Hg, respectively). No subject taking tamsulosin had a decrease in standing SBP less than 85 mm Hg. Tadalafil augmented the hypotensive effects of doxazosin but had little hemodynamic interaction with tamsulosin. In patients taking tadalafil for ED, tamsulosin 0.4 mg may be given for the treatment of benign prostatic hyperplasia.Keywords
This publication has 17 references indexed in Scilit:
- Antihypertensive DrugsPublished by Elsevier BV ,2009
- Time course of the interaction between tadalafil and nitratesJournal of the American College of Cardiology, 2003
- Cardiovascular effects of tadalafil in patients on common antihypertensive therapiesThe American Journal of Cardiology, 2003
- Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: A post-hoc analysis of five placebo-controlled clinical trialsJournal of the American College of Cardiology, 2003
- Overview of the cardiovascular effects of tadalafilEuropean Heart Journal Supplements, 2002
- Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated AnalysesJournal of Urology, 2002
- TamsulosinDrugs & Aging, 2002
- Use of sildenafil (Viagra) in patients with cardiovascular diseaseJournal of the American College of Cardiology, 1999
- Oral Sildenafil in the Treatment of Erectile DysfunctionNew England Journal of Medicine, 1998
- Doxazosin for Benign Prostatic Hyperplasia: Long-term Efficacy and Safety in Hypertensive and Normotensive PatientsJournal of Urology, 1997